The table below details the trials that are currently accruing patients.
|ACTICCA-1- Gallbladder carcinoma||2||50|
|ASCOLT — Colorectal cancer||271||300|
|CONTROL NETs — NeuroEndocrine Tumour||66||72|
|INTEGRATE II – Gastro-Oesophageal||23||350|
|NABNEC — NeuroEndocrine Tumour||16||70|
|TOP GEAR — Stomach cancer||187||752|
Recruitment figures to end January 2017.
Trial Results Lay Summaries (click on the links below):